Technology evaluation: abatacept, Bristol-Myers Squibb

Francis J Dumont1

  • 1Medor Consulting, 421 Dogwood Avenue, Egg Harbor Twp, NJ 08234, USA. francisj_dumont@yahoo.com

Current Opinion in Molecular Therapeutics
|July 22, 2004
PubMed

Bristol-Myers Squibb is developing the fusion protein abatacept for the potential treatment of various immunological disorders, including rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. Abatacept is undergoing phase III clinical trials.

Related Concept Videos